Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer
Authors:
- 1 October 2015
- journal article
- research article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 30 (4) , 382-386
Abstract
Background: The aim of this study was to investigate the impact of number of circulating tumor cells (CTCs) on the treatment outcome for metastatic gastric cancer (GC) following palliative chemotherapy. Methods: CTCs were isolated from 7.5 mL of whole blood from 100 patients with metastatic GC by anti-EpCAM antibody coated magnetic particles using the CTC-Profiler (Veridex). Correlations between CTC counts and clinicopathological variables, progression-free survival and overall survival were examined. Results: Between January 2010 and August 2010, 100 metastatic GC patients were enlisted. Among 100 patients, 5 or more CTCs (CTC-positive) were detected in 27 of 95 patients (28%). Even though the clinical characteristics of the CTC-positive and CTC-negative groups were not significantly different, the treatment response to cytotoxic chemotherapy in the CTC-positive group was significantly poorer (progressive disease: 23.4% vs. 60.0% in CTC-negative vs. CTC-positive group, respectively; p = 0.004). The median progression-free survival of the CTC-positive group was substantially shorter than that of the CTC-negative group (59 days vs. 141 days; p = 0.004). For overall survival, CTC-positive group had significantly shorter survival than CTC-negative group (median OS, 120 days vs. 220 days; p = 0.030). A multivariate Cox proportional hazards regression model showed that CTC positivity was an independent adverse factor for progression-free survival and overall survival. Conclusions: This study suggests CTCs are associated with poor response to chemotherapy in metastatic GC patients.Keywords
This publication has 16 references indexed in Scilit:
- Circulating Tumor Cells: Liquid Biopsy of CancerClinical Chemistry, 2013
- Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancerCancer Science, 2010
- Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate CancerClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- Survival After Gastric Adenocarcinoma Resection: Eighteen-Year Experience at a Single InstitutionJournal of Gastrointestinal Surgery, 2005
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosisScandinavian Journal of Gastroenterology, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen‐receptor status and predicts for poor prognosisInternational Journal of Cancer, 2003